The U.S. Food and Drug Administration has issued a new warning about a popular medication used for weight loss. The FDA says it has received reports of people overdosing on compounded semaglutide, ...
Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...
“Semaglutide is very effective for weight loss,” says Dr. Saunders. In fact, a 2021 phase 3 clinical trial found that 2.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results